Live Aurobindo Pharma Share Price Chart
O 1095.2
H 1095.2
L 1095.2
VOL 516
Aurobindo Pharma Performance
Days Range
Aurobindo Pharma Fundamentals
ROCE (TTM) | 10.1 |
P/E Ratio (TTM) | 23.12 |
P/B Ratio | 2.27 |
Industry P/E | 36.18 |
Debt to Equity | 0.24 |
ROE | 8.25 |
EPS (TTM) | 47.97 |
Dividend Yield | 0.69 |
Book Value | 481.09 |
Face Value | 1 |
Aurobindo Pharma Financials
Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | |
---|---|---|---|---|
Net Sales | 6,472.96 | 6,850.52 | 7,219.42 | 7,351.78 |
Expenses | 5,816.35 | 6,025.71 | 6,263.48 | 6,173.74 |
Profit before tax | 730.06 | 812.03 | 1,075.64 | 1,262.42 |
Operating Profit | 505.91 | 569.71 | 751.94 | 939.97 |
Net Profit | 505.91 | 569.71 | 751.94 | 939.97 |
EPS in Rs | 8.64 | 10.93 | 12.83 | 16.04 |
About Aurobindo Pharma
History of Aurobindo Pharma Limited (APL)
Founded in 1986, Aurobindo Pharma Limited (APL) is a pharmaceutical company that is involved in the development, manufacture and sale of Active Pharma Ingredients (API) and formulations.
The company started their operations in 1988-1989 with a single manufacturing unit at Pondicherry to manufacture Semi Synthetic Penicillins (SSPs). Between 1992-1993, they set up another manufacturing facility in Hyderabad to manufacture CMIC Chloride, a bulk drug intermediate. In 1994, the company merged with Chaitanya Organics Pvt. Ltd and started the commercial production of the pharmaceutical formulation unit. In 1995, Aurobindo Pharma Limited went public. Since then, the company has expanded its product base and started manufacturing various formulations.
From 2003 to 2004, the company set up a subsidiary in China and started commercial production. Between 2005 to 2006, Aurobindo Pharma Limited acquired UK-based Milpharm Limited, which is involved in marketing generic formulations in the UK market. They established their presence worldwide in Brazil, the USA, Puerto Rico and Portugal.
As of March 2023, Aurobindo Pharma Limited has 25 State-of-the-art manufacturing and packaging facilities, with export presence in more than 150 countries, 9 R&D centres and over 1,500 scientists and analysts involved in R&D activities.
Business Segments of Aurobindo Pharma Limited
- API: Under this segment, Aurobindo Pharma Limited develops and manufactures APIs. Their five manufacturing units are inspected and approved by the US FDA, ANVISA, TGA Australia, UK MHRA and other trusted regulatory agencies.
- Antiretroviral (ARV): Under this, the company works with an aim to offer a wide range of high-quality antiretroviral drugs (US FDA Approved) for PLHIV & CLHIV.
- AuroZymes: This is the biocatalysts division of APL that develops and produces biocatalysts that can be utilised in the Chemical and Pharmaceutical Industries.
- Custom Synthesis: In this segment, the company provides customer-centric project-based chemistry services through their custom research and manufacturing division, AuroSource.
- Formulations: Under this segment, APL is involved in cost-effective drug development and substantial manufacturing.
- Peptides: In this segment, the company develops peptide-based generic APIs, specifically focusing on diabetology and oncology segments.
- R&D: The R&D segment of the company is involved in developing new drug delivery systems and new dosage formulations.
As of March 31, 2023, some of the subsidiaries of Aurobindo Pharma Limited are as follows:
- Helix Healthcare B.V.: This subsidiary of the company is involved in the healthcare sector.
- Aurovitas Pharma Polska: This is a wholly-owned subsidiary of the company that focuses on generic, Rx and OTC drugs covering 22 therapeutic areas.
- Milpharm Limited: This wholly-owned subsidiary of the company that manufactures pharma products.
Key Personalities of Aurobindo Pharma Limited
Nityananda Reddy, Managing Director and Chairman
Nityananda Reddy is the Chairman and Managing Director of Aurobindo Pharma Limited. He has been associated with APL since its initial days. He has experience in manufacturing technology and oversees the overall affairs of the company.
Corporate Actions of Aurobindo Pharma Limited
The company issued a bonus share of a 1:1 ratio with a record date of July 21, 2015.
Peer Comparison
Stocks | Market Cap (cr) | Market Price (₹) | 52 Week Low-High (₹) |
---|---|---|---|
Lupin Ltd | ₹72,033.58 |
1580 0.05 (0.00%) |
1559.15 - 1602.7 |
Gland Pharma Ltd | ₹29,346.47 |
1756.7 25.20 (-1.41%) |
1747.3 - 1797 |
Alkem Laboratories Ltd | ₹56,202.13 |
4720.95 16.55 (0.35%) |
4691 - 4759.65 |
Glaxosmithkline Pharmaceuticals Ltd | ₹32,909.66 |
2068 121.25 (6.23%) |
1954.25 - 2087 |
Abbott India Ltd | ₹54,706.64 |
25500 225.10 (-0.88%) |
25405 - 25867.85 |
Popular Stocks
What's Trending
Aurobindo Pharma FAQs
What is the Share price of Aurobindo Pharma (AUROPHARMA)?
Can I buy Aurobindo Pharma (AUROPHARMA) shares?
How do I buy Aurobindo Pharma (AUROPHARMA) from Angel One?
- Direct investment: You can buy Aurobindo Pharma (AUROPHARMA) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Aurobindo Pharma (AUROPHARMA) shares.
Is Aurobindo Pharma a Debt free Company?
No, Aurobindo Pharma is not a debt free company.
What is the main business of Aurobindo Pharma?
The main business of Aurobindo Pharma is to manufacture semi-synthetic penicillin (SSP) through over 27 manufacturing and packaging facilities situated globally. It also has a presence in several therapeutic segments, including neurosciences, gastroenterology, cardiovascular, anti-diabetics, anti-retrovirals, and anti-biotics
Who are the promoters of Aurobindo Pharma?
Some of the promoters of Aurobindo Pharma include Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding), K Nityananda Reddy, Kirthi Reddy Kambam, Venkata Ramprasad Reddy Penaka, and Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd (Jointly Holding).
What are the Subsidiaries that comes under Aurobindo Pharma?
Some of the subsidiaries that come under Aurobindo Pharma are APL Pharma Thai Limited, All Pharma (Shanghai) Trading Company Limited, Aurobindo Pharma USA Inc., Aurobindo Pharma Industria Farmaceutica Ltda, Brazil, Helix Healthcare B.V., The Netherlands, Auro Pharma Inc., Canada, and APL Healthcare Limited.